ClinicalTrials.gg
TerminatedNCT03371381Updated Feb 4, 2025Results posted

An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung

A Phase 1/2 interventional study of JNJ-64041757 and Nivolumab in Adenocarcinoma of Lung, sponsored by Janssen Research & Development, LLC. Terminated at 10 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1/2, Interventional, and Treatment

How we know · 6 judgments

Why this study was terminated
Development of JNJ-64041757 in combination with nivolumab discontinued due to lack of clinical benefit observed in the Phase 1b portion of the study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 19 studies in Adenocarcinoma of Lung with a site in Spain — 3 open to participants now, 5 under way, none of them phase 3. Adenocarcinoma of Lung · Spain.

Enrollment
18th of 18
12 · median 208
Started
2018
the only one that year
Phase 1/2
3 of 19
1 open now
Registered
13th of 19
by date
Lead sponsor
1 of 19
Janssen Research & Development, LLC

Among the 19 studies in Adenocarcinoma of Lung with a site in Spain, this one is the 18th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2018, is one of 3 in phase 1/2, and was the 13th registered.

Adenocarcinoma of Lung

418 studies on the registry are indexed under Adenocarcinoma of Lung; 78 are open to participants now.

Browse Adenocarcinoma of Lung studies →

Open to participants now

3 of the 19 studies in Adenocarcinoma of Lung with a site in Spain are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 57 Adenocarcinoma of Lung studies recruiting now, 36 (63%) set no upper age limit and 10 (18%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Adenocarcinoma of Lung with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate whether the efficacy of JNJ-757 combined with nivolumab is better than the efficacy of nivolumab monotherapy for participants with mesothelin-positive relapsed/refractory Stage IIIB or Stage IV adenocarcinoma of the lung. The open-label study comprises of two parts i.e. Phase 1b (safety run-in) and Phase 2. Phase1b consists of 1 arm whereas Phase 2 is randomized into 2 groups i.e. Group A and Group B.

Read the detailed description

This study evaluates safety and efficacy of JNJ-64041757 with nivolumab. The total study duration will be up to 3 years. It will consist of safety run-in and randomized phase which will comprise of Screening phase(Day(D) -28 to D -1),Treatment Phase,End of Adverse Event Evaluation Period (100 D after last dose of nivolumab)and Post-treatment Follow-up Phase(Every 3 Months). The primary hypothesis is that addition of JNJ-640417577 to nivolumab will result in higher objective response rate compared with nivolumab monotherapy in at least one of programmed death receptor ligand 1 subgroups in participants with relapsed or refractory StageIIIB or StageIV adenocarcinoma of lung. The study procedures include blood culture bacterial shedding assessments, pharmacokinetics, immunogenicity, and biomarkers. Safety will be monitored throughout study.

03

Conditions studied

  • Adenocarcinoma of Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Disease-related criteria: documented adenocarcinoma of the lung; Stage IIIB or Stage IV disease; material available for central assessment of programmed death receptor ligand 1 () and mesothelin
  • (ECOG) performance status of 0 or 1
  • Progressive disease during or after platinum-based doublet chemotherapy
  • A woman of must have a negative serum or urine pregnancy test within 14 days before the first dose of nivolumab
  • Willing and able to adhere to the prohibitions and restrictions specified in this protocol

Exclusion criteria

Exclusion Criteria:

  • Tumor with activating epidermal growth factor receptor (EGFR) mutation or ALK translocation
  • More than 1 for disease (Phase 2)
  • History of disallowed therapies, as follows: In Phase 1b only: Prior exposure to anti-programmed death receptor-1(PD1), anti programmed death receptor ligand 1 (), anti-programmed death receptor ligand 2 (PD-L2), anti-CD137, or anti-cytotoxic T lymphocyte associated antigen 4 (CTLA-4) antibody within 28 days before the first dose of study agent, In Phase 2 only: Prior exposure to anti-PD1, anti PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T lymphocyte associated antigen 4 (CTLA-4) antibody, History of listeriosis or vaccination with a Listeria-based vaccine or prophylactic vaccine within 28 days before the first dose of study agent, Chemotherapy within 28 days before the first dose of study agent, Radiation within 14 days before the first dose of study agent
  • History of any other condition that may require the initiation of anti-tumor necrosis factor alpha (TNF alpha) therapies or other medications during the study
  • Active second within 2 years prior to Cycle 1 Day 1 (Phase 1b) or randomization (Phase 2)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Nivolumab + JNJ-64041757

    Phase 1b and Phase 2 Group A/Arm 1: Participants will receive separate intravenous (IV) infusions of nivolumab and JNJ-64041757 over approximately 60 minutes during each treatment cycle until disease progression, unacceptable toxicity, protocol violation requiring discontinuation of study treatment, withdrawal of consent, noncompliance with study procedures, or the sponsor terminates the study.

    Biological: JNJ-64041757 · Drug: Nivolumab

  • Active comparator
    Nivolumab

    Phase 2 Group B/Arm 2: Participants will receive intravenous (IV) infusions of nivolumab over approximately 60 minutes during each treatment cycle until disease progression, unacceptable toxicity, protocol violation requiring discontinuation of study treatment, withdrawal of consent, noncompliance with study procedures, or the sponsor terminates the study.

    Drug: Nivolumab

Interventions

  • BiologicalJNJ-64041757

    Participants will receive intravenous (IV) infusions of JNJ-64041757 over approximately 60 minutes during each treatment cycle.

    Also known as: JNJ-757

  • Participants will receive IV infusions of nivolumab over approximately 60 minutes during each treatment cycle.

06

What researchers measure

Primary outcomes

  1. Phase 1b: Percentage of Participants With Objective Response

    Objective response rate was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST). RECIST for CR - disappearance of all lesions; all lymph nodes were non-pathological in size and normalization of tumor marker level; PR - greater than or equal to (\>=) 30 percent (%) decrease in the sum of the diameters of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of nontarget lesions.

    Time frame: Up to 6.8 Months

Secondary outcomes

  1. Phase 1b: Duration of Objective Response (DOR)

    Duration of objective response was defined as the time from initial documentation of a response (CR or PR) to first documented date of disease progression (PD) or death from any cause. RECIST for PD - sum of diameters had increased by \>= 20% and \>=5 mm from nadir (including baseline if it was smallest sum). Participants with measurable disease: for "unequivocal progression" based on non-target disease, there was an overall level of substantial worsening that merits discontinuation of therapy (if target disease is stable disease \[SD\]/PR). Participants without measurable disease: for "unequivocal progression" of non-target disease, increase in overall tumor burden must be comparable to increase required for PD of measurable disease. Furthermore, appearance of 1 or more new lesions or unequivocal progression of a non-target lesion.

    Time frame: Up to 6.8 months

  2. Phase 1b: Number of Participants With Progression-free Survival (PFS) Event (Progressed or Died Before Progression)

    Number of participants with PFS event (progressed or died before progression) were reported. PFS - time from date of randomization until date of first documented evidence of PD (or relapse for participants who experience CR during study) or death from any cause, whichever comes first. RECIST for PD - sum of diameters had increased by \>= 20% and \>=5 mm from nadir (including baseline if it was smallest sum). Participants with measurable disease: for "unequivocal progression" based on non-target disease, there was an overall level of substantial worsening that merits discontinuation of therapy (if target disease is SD/PR). Participants without measurable disease: for "unequivocal progression" of non-target disease, increase in overall tumor burden must be comparable to increase required for PD of measurable disease. Furthermore, appearance of 1 or more new lesions or unequivocal progression of a non-target lesion.

    Time frame: Up to 6.8 months

  3. Phase 1b: Number of Participants With Overall Survival (OS) Event (Died)

    Number of participants with OS event (died) were reported. Overall Survival was defined as the duration from the date of randomization to the date of participant's death due to any cause.

    Time frame: Up to 6.8 months

  4. Phase 1b: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as adverse events with onset or worsening on or after date of first dose of study treatment.

    Time frame: Up to 6.8 months

  5. Phase 1b: Number of Participants With Positive Blood Culture

    Number of participants with surveillance cultures positive for listeriosis were reported.

    Time frame: Up to 6.8 months

  6. Phase 1b: Number of Participants With Bacterial Shedding

    Number of participants with bacterial shedding were reported. The shedding of JNJ-64041757 was studied in feces by stool or rectal swab, urine and saliva.

    Time frame: Up to 6.8 months

  7. Phase 1b: Serum Concentrations of Nivolumab

    Nivolumab serum concentrations were reported.

    Time frame: Up to 6.8 months

  8. Phase 1b: Number of Participants With Anti-nivolumab Antibodies

    Number of participants with antibodies to nivolumab were reported.

    Time frame: Up to 6.8 months

07

Results

Posted Dec 11, 2019
Limitations and caveats
Sponsor did not proceed to Randomized phase 2 of study or enroll additional participants in phase 1b as study was stopped early, that resulted in limited evaluation of planned participant-related outcomes, PK, immunogenicity and biomarker analyses.

Participant flow

Participant flow — Overall Study
MilestonePhase 1b: JNJ-64041757+ Nivolumab
Started12
Completed0
Not completed12
Withdrew: Death5
Withdrew: Study terminated by sponsor3
Withdrew: Other4

Outcome measures

PrimaryPhase 1b: Percentage of Participants With Objective Response

Objective response rate was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST). RECIST for CR - disappearance of all lesions; all lymph nodes were non-pathological in size and normalization of tumor marker level; PR - greater than or equal to (\>=) 30 percent (%) decrease in the sum of the diameters of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of nontarget lesions.

Time frame:
Up to 6.8 Months
Reported as:
Number · Percentage of participants
Phase 1b: Percentage of Participants With Objective Response
Percentage of participantsPhase 1b: JNJ-64041757+ Nivolumab
Phase 1b: Percentage of Participants With Objective Response0
SecondaryPhase 1b: Duration of Objective Response (DOR)

Duration of objective response was defined as the time from initial documentation of a response (CR or PR) to first documented date of disease progression (PD) or death from any cause. RECIST for PD - sum of diameters had increased by \>= 20% and \>=5 mm from nadir (including baseline if it was smallest sum). Participants with measurable disease: for "unequivocal progression" based on non-target disease, there was an overall level of substantial worsening that merits discontinuation of therapy (if target disease is stable disease \[SD\]/PR). Participants without measurable disease: for "unequivocal progression" of non-target disease, increase in overall tumor burden must be comparable to increase required for PD of measurable disease. Furthermore, appearance of 1 or more new lesions or unequivocal progression of a non-target lesion.

Time frame:
Up to 6.8 months

No measurements were reported for this outcome.

SecondaryPhase 1b: Number of Participants With Progression-free Survival (PFS) Event (Progressed or Died Before Progression)

Number of participants with PFS event (progressed or died before progression) were reported. PFS - time from date of randomization until date of first documented evidence of PD (or relapse for participants who experience CR during study) or death from any cause, whichever comes first. RECIST for PD - sum of diameters had increased by \>= 20% and \>=5 mm from nadir (including baseline if it was smallest sum). Participants with measurable disease: for "unequivocal progression" based on non-target disease, there was an overall level of substantial worsening that merits discontinuation of therapy (if target disease is SD/PR). Participants without measurable disease: for "unequivocal progression" of non-target disease, increase in overall tumor burden must be comparable to increase required for PD of measurable disease. Furthermore, appearance of 1 or more new lesions or unequivocal progression of a non-target lesion.

Time frame:
Up to 6.8 months
Reported as:
Count of participants · Participants
Phase 1b: Number of Participants With Progression-free Survival (PFS) Event (Progressed or Died Before Progression)
ParticipantsPhase 1b: JNJ-64041757+ Nivolumab
Phase 1b: Number of Participants With Progression-free Survival (PFS) Event (Progressed or Died Before Progression)10
SecondaryPhase 1b: Number of Participants With Overall Survival (OS) Event (Died)

Number of participants with OS event (died) were reported. Overall Survival was defined as the duration from the date of randomization to the date of participant's death due to any cause.

Time frame:
Up to 6.8 months
Reported as:
Count of participants · Participants
Phase 1b: Number of Participants With Overall Survival (OS) Event (Died)
ParticipantsPhase 1b: JNJ-64041757+ Nivolumab
Phase 1b: Number of Participants With Overall Survival (OS) Event (Died)5
SecondaryPhase 1b: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as adverse events with onset or worsening on or after date of first dose of study treatment.

Time frame:
Up to 6.8 months
Reported as:
Count of participants · Participants
Phase 1b: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPhase 1b: JNJ-64041757+ Nivolumab
Phase 1b: Number of Participants With Treatment Emergent Adverse Events (TEAEs)12
SecondaryPhase 1b: Number of Participants With Positive Blood Culture

Number of participants with surveillance cultures positive for listeriosis were reported.

Time frame:
Up to 6.8 months
Reported as:
Count of participants · Participants
Phase 1b: Number of Participants With Positive Blood Culture
ParticipantsPhase 1b: JNJ-64041757+ Nivolumab
Phase 1b: Number of Participants With Positive Blood Culture1
SecondaryPhase 1b: Number of Participants With Bacterial Shedding

Number of participants with bacterial shedding were reported. The shedding of JNJ-64041757 was studied in feces by stool or rectal swab, urine and saliva.

Time frame:
Up to 6.8 months
Reported as:
Count of participants · Participants
Phase 1b: Number of Participants With Bacterial Shedding
ParticipantsPhase 1b: JNJ-64041757+ Nivolumab
Phase 1b: Number of Participants With Bacterial Shedding0
SecondaryPhase 1b: Serum Concentrations of Nivolumab

Nivolumab serum concentrations were reported.

Time frame:
Up to 6.8 months

No measurements were reported for this outcome.

SecondaryPhase 1b: Number of Participants With Anti-nivolumab Antibodies

Number of participants with antibodies to nivolumab were reported.

Time frame:
Up to 6.8 months
Reported as:
Count of participants · Participants
Phase 1b: Number of Participants With Anti-nivolumab Antibodies
ParticipantsPhase 1b: JNJ-64041757+ Nivolumab
Phase 1b: Number of Participants With Anti-nivolumab Antibodies6

Adverse events

Collected over Up to 6.8 months. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1b: JNJ-64041757+ Nivolumab5/12 (41.7%)5/12 (41.7%)12/12 (100%)
Most frequent serious events
Most frequent serious events
EventPhase 1b: JNJ-64041757+ Nivolumab
PneumonitisRespiratory, thoracic and mediastinal disorders2/12
Abdominal PainGastrointestinal disorders1/12
Intestinal ObstructionGastrointestinal disorders1/12
Non-Cardiac Chest PainGeneral disorders1/12
Oedema PeripheralGeneral disorders1/12
ArthralgiaMusculoskeletal and connective tissue disorders1/12
Back PainMusculoskeletal and connective tissue disorders1/12
Musculoskeletal PainMusculoskeletal and connective tissue disorders1/12
DyspnoeaRespiratory, thoracic and mediastinal disorders1/12
ErythemaSkin and subcutaneous tissue disorders1/12
Most frequent other events
Showing 10 of 50
Most frequent other events
EventPhase 1b: JNJ-64041757+ Nivolumab
PyrexiaGeneral disorders8/12
ChillsGeneral disorders7/12
AstheniaGeneral disorders6/12
AnaemiaBlood and lymphatic system disorders5/12
NauseaGastrointestinal disorders5/12
DyspnoeaRespiratory, thoracic and mediastinal disorders5/12
Decreased AppetiteMetabolism and nutrition disorders4/12
VomitingGastrointestinal disorders3/12
HyponatraemiaMetabolism and nutrition disorders3/12
Musculoskeletal PainMusculoskeletal and connective tissue disorders3/12

Baseline characteristics

The all treated analysis population consisted of participants who received at least 1 dose of study agent.

Age, Continuous
Age, Continuous(years)Phase 1b: JNJ-64041757+ Nivolumab
Mean61.2 ± 12.63
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1b: JNJ-64041757+ Nivolumab
Female4
Male8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1b: JNJ-64041757+ Nivolumab
Hispanic or Latino1
Not Hispanic or Latino11
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1b: JNJ-64041757+ Nivolumab
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White12
More than one race0
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 1b: JNJ-64041757+ Nivolumab
Hispanic or Latino1
White Non-Hispanic11
Region of Enrollment
Region of Enrollment(Participants)Phase 1b: JNJ-64041757+ Nivolumab
SPAIN10
UNITED STATES2
08

Study locations

10 sites
  • Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland 21287, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37201, United States
  • Medical Oncology Associates, PS
    Spokane, Washington 99208-1129, United States
  • AZ Maria Middelares
    Gent, 9000, Belgium
  • Hosp. Univ. Quiron Dexeus
    Barcelona, 08028, Spain
  • Hosp. Gral. Univ. de Elche
    Elche, 03203, Spain
  • Complejo Hospitalario de Jaen
    Jaén, 23007, Spain
  • Hosp Regional Univ de Malaga
    Málaga, 29010, Spain
  • Hosp. Son Llatzer
    Palma de Mallorca, 07198, Spain
  • Hosp. Arnau de Vilanova de Valencia
    Valencia, 46015, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Oct 2018, 9 months.

Results were first posted in Dec 2019, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2017
First posted
Dec 13, 2017
StartActual
Jan 2, 2018
Primary completionActual
Oct 9, 2018
CompletionActual
Oct 9, 2018
Results first posted
Dec 11, 2019
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03371381
Responsible party
Sponsor
First posted
Dec 13, 2017
Start date
Jan 2, 2018
Primary completion
Oct 9, 2018
Completion
Oct 9, 2018
Results posted
Dec 11, 2019
Last update
Feb 4, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion